By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
CHOOSE YOUR LANGUAGE
CHOOSE YOUR LANGUAGE
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466
Visitors at the 7th China International Import Expo in Shanghai on November 5./ CFP
Editor's note: Bill Anderson is CEO of Bayer. The article reflects the author's opinions and not necessarily the views of CGTN.
From November 5 to 10, the highly anticipated 7th China International Import Expo (CIIE) is held in Shanghai. As a window for China to build a new development pattern, a platform for promoting high-level opening-up, the CIIE, with the theme of "New Era, Shared Future" this year, will bring new opportunities to all countries and regions.
By participating in the CIIE for seven consecutive years, Bayer has not only witnessed the vigorous development of the Chinese market, but also achieved in-depth communication and cooperation with global partners through this platform.
For Bayer, a seven-time participant and "old friend" of the CIIE, China has always been a strategic market. The 7th CIIE is a great opportunity to showcase our innovative products and cutting-edge technology while engaging with a wide spectrum of partners on this one-of-a-kind platform.
Capitalizing on the "incubator" effect of the CIIE, Bayer has exhibited over 100 innovative items, incubated 8 "CIIE babies," and inked over 30 major agreements across various fields over the past six years.
More than 3,000 exhibitors gathered at the 7th China International Import Expo at the Shanghai National Convention and Exhibition Center on November 5./ CFP
This year, Bayer takes its bold mission, "Health for All, Hunger for None," as the theme and presented innovations from three divisions: Pharmaceuticals (and Radiology), Consumer Health and Crop Science, and continued exhibiting in two subsections, with a total space of record-high 800 square meters.
Since entering China, Bayer has invested heavily in local projects to boost innovation. Whether in the fields of Pharmaceuticals, Consumer Health, or Crop Science, and from both R&D and market perspectives, China is one of Bayer's most important strategic pillars.
Bayer has been developing in China for more than 140 years and has an unwavering commitment to Chinese patients, consumers and growers. We will continue to deepen our presence in China by enhancing local production capabilities and actively seeking collaboration opportunities with local research institutions and innovative companies. These efforts aim to support China's national strategies, including Healthy China, Rural Revitalization, and sustainable development.